
It was announced that the drug containing the active ingredient Daraxonrasib increased the life expectancy to 16 months in lung cancer patients who did not respond to standard treatments.
AI-generated summary
RAS protein mutations are genetic changes that trigger the uncontrolled proliferation of cancerous cells and are difficult to target with traditional methods.
The pancreatic cancer drug Rasonque (its active ingredient daraxonrasib), which has been recorded as a historical clinical success in the medical world, this time appeared on the scene against lung cancer, which causes the most deaths on a global scale. A new study published just after the official approval of the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer documented the high therapeutic power of the drug on lung tumors. Clinical trial data published in the respected medical journal New England Journal of Medicine offered satisfactory results in patients who did not respond to previously applied standard chemotherapy and targeted treatments.
IT INCREASED LIFE EXPENSE TO 16 MONTHS BY DIRECTLY SHRINKING TUMORS
136 patients diagnosed with "non-small cell lung cancer", the most common type of lung cancer, and carrying the "RAS" protein mutation participated in the study conducted at Memorial Sloan Kettering Cancer Center. In clinical trials, it was found that daraxonrasib, taken in daily tablet form, significantly reduced tumor sizes in more than 30% of patients.
The drug, which extends the survival time by an average of 5 months to 16 months compared to patients receiving standard chemotherapy, is nominated to set a new standard in lung cancer treatment.
MOLECULAR GLUE LOCKS THE "RAS" PROTEINS, SO-CALLED UNTARGEABLE
Mutated RAS proteins, which have been considered "undruggable" in the medical literature for many years due to their structure, trigger the uncontrolled proliferation of cancerous cells. The active ingredient daraxonrasib, developed by the biotechnology company Revolution Medicines, acts like a "molecular glue" and locks the cancer-triggering mechanism of these proteins.
The molecular mechanism in question is not only in the pancreas and lung; It has been noted that it can neutralize RAS mutations seen in intestinal (colorectal), intrauterine (endometrium) and skin (melanoma) cancers.
COMPREHENSIVE PHASE III STUDIES HAVE BEEN STARTED
Following the clinical success of the drug, great momentum was gained in the world of medicine and pharmacy. Currently, 79 different RAS inhibitors have reportedly been tested in 241 active clinical trials worldwide.
Within the scope of ongoing Phase III studies, lung cancer patients are randomly divided into chemotherapy and daraxonrasib groups and the long-term resistance mechanisms and success rates of the drug are examined. Experts emphasize that the method, which will be supported by combination treatments, will receive official approval for other types of cancer in the near future.
AI outlook — possibilities, not facts
Daraxonrasib receives official approval for other types of cancer.
Likely · Within months
Belgian Public Health Institute Sciensano announced that there were 2,935 more deaths than expected in the three heat waves between June 18 and August 16. The highest daily death toll occurred on June 27, with 641 deaths.
Minister of Health Kemal Memişoğlu, in his statement on the occasion of Public Health Week, stated that they will be on the field with different themes for 7 days in 81 provinces. The Minister emphasized that millions of scans and early diagnoses have been carried out within the scope of preventive health services.

According to MHRA data in the UK, thousands of side effects and suspicious deaths have been reported about GLP-1 group drugs such as Mounjaro, Wegovy and Saxenda. Authorities emphasized that these reports were not directly related to the drug and that the benefit-risk balance was maintained.

Pediatric Hematology and Oncology Specialist Prof. Dr. İbrahim Bayram drew attention to the risk-increasing effects of air pollution, pesticides and chemical waste on childhood cancers, especially leukemia and lymphoma.

Nurses Serpil Uslu, Fikriye Özkan, Ferhan Naz Kırkçeşmeli and secretary Şafak Kara, working at Kastamonu Training and Research Hospital, overcame breast cancer, which they contracted in the same period, by supporting each other.

Research shows that nutrition affects mental health through blood sugar and gut health. Experts offer four practical suggestions to support mood: eating regularly, drinking water, reducing processed foods and adding plant-based foods.